Gilead Sciences, Inc. (GILD) Expands U.S. Manufacturing Capacity With $32B Investment Through 2030

Core Insights - Gilead Sciences, Inc. is recognized for its leadership in antiviral and oncology therapies, leveraging AI to enhance precision medicine and global patient access [1][2] Group 1: Investment and Infrastructure - Gilead Sciences is investing $32 billion in the U.S. through 2030 to strengthen domestic manufacturing and integrate AI into operations [2][4] - A new 180,000-square-foot Pharmaceutical Development and Manufacturing Technical Development Center is being established, featuring advanced technologies like autonomous robotics and real-time digital monitoring [2][3] Group 2: Product Development and Global Health Impact - The new facility aims to improve data-driven insights and process automation for therapies, including CAR-T treatments and next-generation antivirals [3] - Gilead is partnering with PEPFAR to provide lenacapavir for HIV prevention, targeting up to two million individuals in low- and lower-middle-income countries by the end of 2025 [4]